Novel treatment
for solid tumours
with no detectable
systemic toxicity
Gordian Pharma is developing MTL-004, a localised therapeutic,
Localised Delivery
Direct application to the tumour site to maximise local impact.
Long Lasting Activity
Sustained presence at the treatment site for up to 28 days.
Reduced Systemic Toxicity
No detectable systemic toxicity at the therapeutic
doses studied.
Potential for Broad Applications
Applicable across a range of solid tumour indications.